Publications by Lucia Bonati | EPFL Graph Search

Rational cytokine and receptor engineering for enhanced safety and efficacy of cancer immunotherapy

The emergence of immunotherapy, including immune checkpoint blockade (ICB) and the adoptive transfer of cytotoxic lymphocytes, such as CAR-T cell therapy, has revolutionized cancer treatment. However, these therapies still face significant challenges in t ...

EPFL2025

The type 2 cytokine Fc–IL-4 revitalizes exhausted CD8+ T cells against cancer

Li Tang, Lucia Bonati, Mei-Wen Peng, Rongrong Li, Yugang Guo, Yang Zhao, Bing Feng

Current cancer immunotherapy predominately focuses on eliciting type 1 immune responses fighting cancer; however, long-term complete remission remains uncommon1,2. A pivotal question arises as to whether type 2 immunity can be orchestrated alongside type 1 ...

2024

Evidence and therapeutic implications of biomechanically regulated immunosurveillance in cancer and other diseases

Li Tang, Lucia Bonati

Disease progression is usually accompanied by changes in the biochemical composition of cells and tissues and their biophysical properties. For instance, hallmarks of cancer include the stiffening of tissues caused by extracellular matrix remodelling and t ...

Nature Portfolio2024

Rational Design of Chemically Controlled Antibodies and Protein Therapeutics

Li Tang, Bruno Emanuel Ferreira De Sousa Correia, Sandrine Madeleine Suzanne Georgeon, Anthony Marchand, Leo Scheller, Lucia Bonati, Pablo Gainza Cirauqui, Stéphane Rosset, Sailan Shui

Protein-based therapeutics, such as monoclonal antibodies and cytokines, are important therapies for various pathophysiological conditions such as oncology, autoimmune disorders, and viral infections. However, the wide application of such protein therapeut ...

2023

Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy

Georg Fantner, Mahmut Selman Sakar, Li Tang, Lucia Bonati, Murat Kaynak, Mélanie Thérèse Marie Hannebelle, Yugang Guo, Yuqing Xie, Min Gao, Armand Kurum

Cancer cells enriched in cholesterol in their plasma membrane impair T-cell-mediated cytotoxicity, which can be augmented by stiffening the cancer cells via cholesterol depletion, as shown in mouse models of adoptive T-cell immunotherapy. Malignant transfo ...

2021

Cytokine engineering for targeted cancer immunotherapy

Li Tang, Lucia Bonati

Cytokines are key modulators of the immune responses and represent promising therapeutics for a variety of cancers. However, successful translation of cytokine-based therapy to the clinic is limited by, among others, severe toxicities and lack of efficacy ...

2021

Liposome nano-formulation with cationic polar lipid DOTAP and cholesterol as a suitable pH-responsive carrier for molecular therapeutic drug (all-trans retinoic acid) delivery to lung cancer cells

Lucia Bonati

The molecular targeted drug ATRA demands a suitable carrier that delivers to the cancer site due to its poor bioavailability and drug resistance. ATRA, being a lipid with carboxylic acid, has been nano-formulated as a cationic lipo-ATRA with DOTAP:choleste ...

WILEY2021